NewAmsterdam Pharma Company N.V. (NAMSW) Stock Analysis

NewAmsterdam Pharma Company N.V. (NAMSW) Healthcare & Pipeline Overview

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company dedicated to developing oral therapies for metabolic diseases, with a focus on its innovative CETP inhibitor, obicetrapib, which aims to improve cholesterol levels and cardiovascular health.

What Is the Investment Thesis for NAMSW?

NewAmsterdam Pharma Company N.V. presents a compelling investment thesis driven by its innovative approach to treating metabolic diseases through obicetrapib, which has demonstrated efficacy in clinical trials. The company's gross margin stands at an impressive 97.5%, indicating strong potential for profitability once it commercializes its products. With a market cap of $3.67B, NewAmsterdam Pharma is well-positioned to capture a share of the growing cardiometabolic disease market, which is expected to expand significantly due to rising obesity rates and associated health issues. The company's low beta of 0.08 suggests lower volatility compared to the broader market, providing a degree of stability for investors. However, risks remain, including potential regulatory hurdles and competition from established cholesterol-lowering therapies. Investors should monitor the outcomes of ongoing clinical trials and upcoming regulatory decisions as key indicators of the company's future performance.

Based on FMP financials and quantitative analysis

NAMSW Key Highlights

Market cap of $3.67B reflects strong investor interest in innovative biopharmaceutical solutions.

• Gross margin of 97.5% indicates a high potential for profitability upon product commercialization.
• Beta of 0.08 suggests lower volatility compared to the broader market, offering stability for investors.
• Currently has no dividend yield, focusing all resources on clinical development.
• Profit margin of -942.8% reflects the early-stage nature of the company as it invests heavily in R&D.

Who Are NAMSW's Competitors?

NAMSW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NAMSW's Key Strengths?

Innovative product pipeline with obicetrapib showing promising clinical results.

• High gross margin indicating potential for profitability post-commercialization.
• Strong focus on research and development to address unmet medical needs.
• Experienced leadership team with a track record in biopharmaceuticals.

What Are NAMSW's Weaknesses?

Currently no revenue as the company is in the clinical development phase.

• High profit margin of -942.8% reflecting significant R&D investments.
• Limited product portfolio focused primarily on obicetrapib.
• Dependence on successful clinical trial outcomes and regulatory approvals.

What Could Drive NAMSW Stock Higher?

Completion of Phase 3 clinical trials for obicetrapib, expected in Q4 2026.

• Anticipated regulatory submission for obicetrapib in early 2027.
• Continuous engagement with healthcare providers to prepare for product launch.
• Monitoring and adapting to competitive landscape developments in cholesterol therapies.
• Ongoing investor relations efforts to secure funding for further R&D.

What Are the Key Risks for NAMSW?

Negative return on equity (-29.8%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $3.7M recently.
• Regulatory hurdles that could impact the approval timeline for obicetrapib.
• Competition from established cholesterol-lowering medications that may affect market entry.
• Delays in clinical trial results could hinder strategic planning and investor confidence.
• Market volatility impacting funding and investor sentiment regarding biopharmaceutical stocks.

What Are the Growth Opportunities for NAMSW?

• Growth opportunity 1: The global market for cholesterol-lowering therapies is expected to reach $20 billion by 2028, driven by rising obesity rates and cardiovascular diseases. NewAmsterdam Pharma's obicetrapib, with its dual action of lowering LDL-C and raising HDL-C, positions the company to capture a significant share of this market as it advances through clinical trials and regulatory approvals.
• Growth opportunity 2: The increasing prevalence of metabolic diseases globally is projected to grow at a CAGR of 6% over the next five years. NewAmsterdam Pharma's focus on innovative oral therapies for these conditions aligns with market needs, providing an opportunity for the company to expand its product offerings and address unmet medical needs.
• Growth opportunity 3: Collaborations with healthcare providers and research institutions can enhance NewAmsterdam Pharma's clinical trial capabilities and accelerate the development of obicetrapib. Strategic partnerships may also facilitate access to broader patient populations, expediting the path to market and increasing the likelihood of successful outcomes.
• Growth opportunity 4: The company's innovative approach to CETP inhibition could lead to additional pipeline products targeting other metabolic disorders. By leveraging its expertise in drug development, NewAmsterdam Pharma can diversify its product portfolio and reduce dependency on a single product, enhancing long-term growth prospects.
• Growth opportunity 5: As regulatory bodies increasingly prioritize expedited pathways for innovative therapies, NewAmsterdam Pharma may benefit from faster approval processes for obicetrapib. This could allow the company to bring its product to market sooner, capitalizing on early mover advantages in the competitive landscape.

What Threats Does NAMSW Face?

• Regulatory hurdles that could delay product approvals and market entry.
• Intense competition from established pharmaceutical companies with existing therapies.
• Market volatility impacting investor sentiment and funding availability.
• Potential changes in healthcare regulations affecting pricing and reimbursement.

What Are NAMSW's Competitive Advantages?

• Innovative drug development focused on a unique mechanism of action (CETP inhibition).
• Strong intellectual property portfolio protecting its product candidates.
• Positive clinical trial results enhancing credibility and investor confidence.
• Dedicated and experienced management team with expertise in biopharmaceuticals.
• Focus on oral therapies, improving patient compliance and treatment adherence.

What Does NAMSW Do?

NewAmsterdam Pharma Company N.V., founded in 2019 and headquartered in Naarden, Netherlands, is a biopharmaceutical company specializing in the development of therapies for metabolic diseases. The firm is currently in the clinical development phase, focusing on its lead product, obicetrapib, a selective Cholesteryl Ester Transfer Protein (CETP) inhibitor. This innovative treatment has shown promise in clinical trials for its ability to lower 'bad' low-density lipoprotein cholesterol (LDL-C) while simultaneously raising 'good' high-density lipoprotein cholesterol (HDL-C). With a dedicated workforce of 68 employees, NewAmsterdam Pharma is committed to enhancing therapeutic options for patients suffering from cardiometabolic diseases, a growing concern in global health. The company's strategic emphasis on oral therapies positions it favorably within the biopharmaceutical landscape, catering to a significant market need. As it advances through clinical trials, NewAmsterdam Pharma aims to establish itself as a leader in the treatment of metabolic disorders, leveraging its innovative approach and robust clinical data to navigate the competitive landscape effectively.

What Products and Services Does NAMSW Offer?

• Develop innovative therapies for metabolic diseases, focusing on cholesterol management.
• Conduct clinical trials to evaluate the efficacy and safety of obicetrapib.
• Inhibit Cholesteryl Ester Transfer Protein (CETP) to improve cholesterol levels.
• Utilize a dedicated team of professionals to advance drug development.
• Focus on oral therapies to enhance patient compliance and treatment outcomes.
• Engage with regulatory bodies to navigate the approval process for new therapies.

How Does NAMSW Make Money?

• Generate revenue through the commercialization of innovative biopharmaceutical products.
• Focus on research and development to create therapies addressing unmet medical needs.
• Leverage clinical trial results to attract investment and partnerships.
• Utilize intellectual property protections to maintain competitive advantages.
• Seek strategic collaborations to enhance research capabilities and market access.

What Industry Does NAMSW Operate In?

The biotechnology industry, particularly within the healthcare sector, is experiencing significant growth driven by advancements in drug development and an increasing prevalence of metabolic diseases. The global market for cholesterol-lowering therapies is projected to expand as awareness of cardiovascular health rises. NewAmsterdam Pharma operates in a competitive landscape alongside peers such as Legend Biotech Corporation (LEGN), Scholar Rock Holding Corporation (SRRK), Amicus Therapeutics, Inc. (FOLD), and Kiniksa Pharmaceuticals, Ltd. (KNSA), all of which are also focused on innovative therapeutic solutions. The increasing demand for effective treatments for metabolic disorders presents a favorable environment for NewAmsterdam Pharma as it progresses through clinical trials and seeks to bring its products to market.

Who Are NAMSW's Key Customers?

• Patients suffering from metabolic diseases, particularly those with cholesterol-related conditions.
• Healthcare providers and physicians seeking effective treatment options for their patients.
• Pharmaceutical distributors and pharmacies involved in the supply chain of biopharmaceutical products.
• Investors interested in the biopharmaceutical sector and innovative healthcare solutions.
• Research institutions and academic partners engaged in clinical studies and drug development.

Company Profile

NewAmsterdam Pharma Company N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Naarden, NL. The company is led by CEO Michael Harvey Davidson Facp.. NAMSW has traded publicly since 2021.

NewAmsterdam Pharma Company N.V. Financial Trajectory

NewAmsterdam Pharma Company N.V. (NAMSW) reported $3.0M in revenue for Q1 2026, reflecting 9400.0% growth compared to the prior quarter. The company recorded a net loss of $48.4M, with diluted EPS of $-0.40. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, NAMSW averaged $-0.45 in diluted EPS.

How NewAmsterdam Pharma Company N.V. Is Valued

NewAmsterdam Pharma Company N.V. carries a market capitalization of $3.67B, placing it in the mid-cap category.

Return on equity for NewAmsterdam Pharma Company N.V. stands at -29.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.2%, the inverse of the P/E and a quick read on earnings relative to price.

NewAmsterdam Pharma Company N.V.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 25.59 places it in the safe zone, indicating low near-term bankruptcy risk.

NewAmsterdam Pharma Company N.V. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.0% below estimates on average.

Wall Street analysts project NewAmsterdam Pharma Company N.V. revenue of about $30.3M for fiscal 2026, with EPS near $-1.89. The estimate reflects 16 contributing analysts.

Over the past six months, NewAmsterdam Pharma Company N.V. insiders filed 15 SEC Form 4 transactions — 9 sales and 6 purchases. On net that is roughly 80K shares disposed (about $3.7M), a signal worth weighing alongside the fundamentals.

NAMSW Financials

NAMSW Latest News

NAMSW Analyst Consensus

NAMSW MoonshotScore

NAMSW Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources